| CXCR3 Protein | |
|---|---|
| Protein Name | C-X-C Motif Chemokine Receptor 3 (CXCR3) |
| Gene Symbol | [CXCR3](/genes/cxcr3) |
| UniProt ID | P49682 |
| Molecular Weight | ~40 kDa (glycosylated), ~35 kDa (core) |
| Subcellular Localization | Cell membrane (GPCR), intracellular pools |
| Protein Family | CXC chemokine receptor family (Class A GPCR) |
| Brain Expression | T cells, NK cells, microglia, astrocytes, neurons |
| Ligands | CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC) |
| Signaling | Gαi/o protein-coupled, β-arrestin recruitment |
CXCR3 is a seven-transmembrane G protein-coupled receptor (GPCR) that serves as the primary receptor for three interferon-gamma (IFN-γ)-inducible chemokines: CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC)[1]. As a key coordinator of T cell trafficking and immune surveillance, CXCR3 plays a central role in directing effector T cells toward sites of inflammation. In the central nervous system (CNS), the CXCR3/CXCL10 axis is a major driver of neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and other neurodegenerative conditions[2].
The significance of CXCR3 in neurodegeneration extends beyond its canonical role in T cell recruitment. The receptor is expressed on microglia, astrocytes, and even neurons, where it contributes to disease-specific inflammatory cascades. The elevated expression of its ligands — particularly CXCL10 — in affected brain regions of AD and PD patients, combined with the accumulation of CXCR3+ immune cells in neuropathological lesions, makes the CXCR3/CXCL10 axis one of the most consistently implicated chemokine pathways in neurodegenerative disease[3][4].
CXCR3 belongs to the rhodopsin-like (Class A) family of GPCRs, characterized by their seven transmembrane alpha-helices (TM1-TM7) connected by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3)[5]. The transmembrane domain forms a bundlelike structure with a ligand-binding pocket accessible from the extracellular space. The receptor has:
CXCR3 binds three closely related chemokines with different affinities:
| Ligand | Alternative Name | CXCR3 Binding Affinity | Induction |
|---|---|---|---|
| CXCL9 | MIG (Monokine induced by IFN-γ) | Moderate (Kd ~ 1-10 nM) | IFN-γ, IFN-α |
| CXCL10 | IP-10 (Interferon gamma-inducible protein of 10 kDa) | High (Kd ~ 0.1-1 nM) | IFN-γ, IFN-α, TNF-α |
| CXCL11 | I-TAC (Interferon-inducible T cell alpha chemoattractant) | Very high (Kd ~ 0.01-0.1 nM) | IFN-γ, IFN-α |
All three ligands share a common ELR motif-negative CXC chemokine structure and are induced primarily by type I and type II interferons, establishing a direct link between antiviral and anti-tumor immune responses and T cell trafficking[1:1].
CXCR3 signals exclusively through Gαi/o proteins (predominantly Gαi2), resulting in:
β-arrestin recruitment (arrestin-2/3) is also robust, enabling:
In the healthy CNS, a small population of tissue-resident memory T cells (TRM cells) provides immune surveillance against pathogens and tumors. CXCR3 plays a critical role in the recruitment of these cells:
The normal healthy brain maintains a tightly regulated balance where sufficient immune surveillance is maintained without excessive inflammatory cell influx. CXCR3 signaling is under homeostatic regulation to prevent inappropriate T cell infiltration.
Microglia express CXCR3 at low levels under normal conditions, where it may participate in:
CXCR3 expression has been reported on select neuronal populations, particularly in the hippocampus and cortex. Neuronal CXCR3 signaling may modulate synaptic function and neurogenesis, though this area remains less well-characterized.
The CXCR3/CXCL10 axis is consistently implicated in AD across multiple lines of evidence[3:1]:
CXCR3 mediates the recruitment of peripheral T cells into the AD brain through the blood-brain barrier[1:2]. IFN-γ-producing CXCR3+ T cells (predominantly CD8+ TEM and CD4+ Th1 subsets) traffic into the CNS in response to CXCL10 gradients emanating from activated microglia and astrocytes surrounding amyloid plaques. This adaptive immune infiltration contributes to:
The T cell infiltration may represent an initial attempt to clear pathological aggregates, but in chronic AD, this response becomes self-sustaining and neurotoxic.
CXCR3 expression on microglia is upregulated by IFN-γ and by amyloid-beta exposure itself[7]. Microglial CXCR3 activation by CXCL10:
CXCR3/CXCL10 signaling intersects with both major AD pathological hallmarks:
Infiltrating CXCR3+ T cells and activated microglia produce factors that impair synaptic function:
Several approaches targeting the CXCR3/CXCL10 axis are in development[8]:
CXCR3+ immune cells are prominent in the substantia nigra pars compacta of PD patients, and the CXCR3/CXCL10 axis is strongly implicated in dopaminergic neurodegeneration[4:1]:
CXCR3+ CD8+ T cells infiltrate the substantia nigra in response to CXCL10 gradients and contribute directly to dopaminergic neuron death[4:2]:
A landmark study used CXCR3-deficient mice to demonstrate that CXCR3 deletion dramatically accelerates alpha-synuclein pathology and dopaminergic degeneration in a mouse model of PD (alpha-synuclein pre-formed fibril injection)[9]. This surprising result — that removing the receptor paradoxically worsens disease — suggests that:
This finding underscores the importance of precise temporal and cellular targeting when developing CXCR3-directed therapies.
CXCR3 signaling on nigral microglia drives their activation and neurotoxic mediator production. CXCL10 treatment of microglial cultures induces production of TNF-α, IL-1β, and nitric oxide (NO), all of which are directly toxic to dopaminergic neurons. Astrocytes also express CXCR3, and activation drives their reactive phenotype, reducing their neuroprotective supportive functions.
The contradictory results from CXCR3 deletion (accelerated pathology in some models) suggest that:
The CXCR3/CXCL10 axis is one of the most well-established therapeutic targets in MS[10]:
In ALS, CXCR3+ T cells are found in spinal cord lesions, and their frequency correlates with disease progression rate[11]:
CXCR3 contributes to secondary injury following TBI through excessive T cell infiltration and neuroinflammation[12]:
CXCR3/CXCL10 signaling increases with normal aging, contributing to the age-related neuroinflammatory state ("inflammaging")[13]:
| Strategy | Agent | Mechanism | Status |
|---|---|---|---|
| CXCR3 antagonist | AMG 487 | Small molecule, competitive inhibition | Preclinical |
| CXCR3 antagonist | T confluence | Small molecule | Preclinical |
| CXCR3 antagonist | Navarixin (SCH 546739) | Small molecule | Phase 2 (asthma, completed) |
| CXCR3 mAb | Ulituximab | Anti-CXCR3 monoclonal antibody | Preclinical oncology |
| CXCL10 mAb | BMS-986253 | Neutralizing anti-CXCL10 | Phase 1/2 (oncology) |
| CXCR3 decoy | CXCR3-Fc | Engineered receptor-Fc fusion | Preclinical |
| JAK inhibitor | Tofacitinib | Reduces CXCL10 induction (upstream) | Rheumatoid arthritis approved |
| JAK inhibitor | Ruxolitinib | Reduces CXCL10 induction (upstream) | Myelofibrosis approved |
Gimenez MC, et al. CXCR3 in neuroinflammation: a master regulator of T cell trafficking in CNS autoimmunity and neurodegeneration. Trends in Neurosciences. 2023. ↩︎ ↩︎ ↩︎
Lacotte S, et al. The role of chemokines in neurodegeneration: a 20-year perspective. Trends in Pharmacological Sciences. 2019. ↩︎
Windsor K, et al. CXCR3/CXCL10 axis in Alzheimer's disease: from adaptive immunity to neuroinflammation. Acta Neuropathologica. 2024. ↩︎ ↩︎
Chen Y, et al. CXCR3+ T cells in Parkinson's disease: accumulation in the substantia nigra and contribution to dopaminergic neurodegeneration. Brain. 2023. ↩︎ ↩︎ ↩︎
Zlotnik A, et al. Chemokines and chemokine receptors in health and disease: a 30-year perspective. Journal of Molecular Medicine. 2017. ↩︎
Wang X, et al. CSF CXCL10 as a biomarker of disease progression and therapeutic response in Alzheimer's disease. Alzheimer's & Dementia. 2024. ↩︎
Koh SH, et al. CXCR3 signaling in microglia and its contribution to neurodegenerative inflammation. Glia. 2023. ↩︎
Bailey SL, et al. Small molecule CXCR3 antagonists in neuroinflammatory disease: from bench to bedside. Expert Opinion on Investigational Drugs. 2024. ↩︎
Chen P, et al. CXCR3 deficiency accelerates alpha-synuclein pathology and dopaminergic degeneration in a mouse model of Parkinson's disease. Journal of Clinical Investigation. 2019. ↩︎
Reijerkerk A, et al. CXCR3 in multiple sclerosis: from CSF biomarker to therapeutic target. Neurology. 2022. ↩︎
Park J, et al. CXCL10/CXCR3 axis in ALS: evidence for immune cell infiltration and disease progression markers. Acta Neuropathologica Communications. 2023. ↩︎
Yang Q, et al. CXCR3 antagonist (AMG 487) reduces neuroinflammation and improves outcomes in a mouse model of traumatic brain injury. Journal of Neuroinflammation. 2022. ↩︎
Rocca E, et al. The role of CXCR3 in aging and age-related cognitive decline. Frontiers in Aging Neuroscience. 2021. ↩︎